Chronic diseases are major cost factors in the health care systems of industrialized countries worldwide due to the need for lifelong treatment and care.

Of the direct health costs - over 430 billion in Germany - around 25% are incurred by the costs of cardiovascular and kidney diseases (including heart failure).

Of these,after 2 yearsalready aSavings of 30%, up to 30 billion per year. In addition, the dynamic spread of these diseases, one of the major cost drivers, can be stopped.

The timely detection of chronic diseases through proteomic tests at the molecular level, before organ damage has occurred, enables

• timely initiation of therapy,
• improved therapy compliance through defined disease status for the first time,
• the individualized, targeted treatment of the patient through proteome-based monitoring,
• ultimately preventing the onset of a chronic disease.